Union européenne -
français -
EMA (European Medicines Agency)
zinbryta
biogen idec ltd - daclizumab - sclérose en plaque - immunosuppresseurs - zinbryta est indiqué chez les patients adultes pour le traitement des formes récurrentes de la sclérose en plaques (rms).
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
zinbryta injektionslösung in einer fertigspritze
biogen switzerland ag - daclizumabum beta - injektionslösung in einer fertigspritze - daclizumabum beta 150 mg, dinatrii succinas, acidum succinicum, natrii chloridum, polysorbatum 80, aqua ad iniectabilia q.s. ad solutionem pro 1 ml. - multiple sklerose - biotechnologika
Suisse -
français -
Swissmedic (Swiss Agency for Therapeutic Products)
zinbryta pen injektionslösung in einem fertigpen
biogen switzerland ag - daclizumabum beta - injektionslösung in einem fertigpen - daclizumabum beta 150 mg, dinatrii succinas, acidum succinicum, natrii chloridum, polysorbatum 80, aqua ad iniectabilia q.s. ad solutionem pro 1 ml. - multiple sklerose - biotechnologika
Canada -
français -
Health Canada
zenapax 5mg/ml liquide
hoffmann-la roche limited - daclizumab - liquide - 5mg - daclizumab 5mg - immunosuppressive agents
Canada -
français -
Health Canada
zinbryta solution
biogen canada inc - daclizumab bêta - solution - 150mg - daclizumab bêta 150mg - immunomodulatory agents
Canada -
français -
Health Canada
zinbryta solution
biogen canada inc - daclizumab bêta - solution - 150mg - daclizumab bêta 150mg - immunomodulatory agents